Exhaled breath analysis for monitoring response to treatment in advanced lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 6, 2016, Pages 827-837

  Nardi Agmon, Inbar ^a   Abud Hawa, Manal ^b   Liran, Ori ^a   Gai Mor, Naomi ^a   Ilouze, Maya ^c   Onn, Amir ^a   Bar, Jair ^a   Shlomi, Dekel ^a   Haick, Hossam ^a,b   Peled, Nir ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Biomarkers; Early detection; Exhale breath; Lung cancer

Indexed keywords

ALPHA PHELLANDRENE; CARBOPLATIN; CISPLATIN; DODECANE; GOLD NANOPARTICLE; NANOMATERIAL; PEMETREXED; POLYETHYLENE TEREPHTHALATE; PROTEIN TYROSINE KINASE INHIBITOR; SINGLE WALLED NANOTUBE; STYRENE; VOLATILE ORGANIC COMPOUND; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; EXPIRED AIR; FEMALE; HUMAN; LUNG CANCER; MALE; MASS FRAGMENTOGRAPHY; NANOARRAY; ONCOLOGIST; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SENSOR; SYSTEMIC THERAPY; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; BREATH ANALYSIS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EXHALATION; FOLLOW UP; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREATH TESTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; EXHALATION; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; VOLATILE ORGANIC COMPOUNDS;

EID: 84979782571     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.02.017     Document Type: Article

References (45)

1. Bruzzi JF, Truong M, Zinner R, Erasmus JJ, Sabloff B, Munden R. Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. J Thorac Oncol. 2006;1:425-429.
2. Pujol JL, Lehmann M, Gautier, et al. Lung cancer chemotherapy. Response-survival relationship depends on the method of chest tumor response evaluation. Am J Respir Crit Care Med. 1966;153:243-249.
3. Werner-Wasik M, Xiao Y, Peguignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys. 2001;41:56-61.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
5. Tisch U, Haick H. Nanomaterials for cross-reactive sensor arrays. MRS Bull. 2010;35:797-803.
6. Tisch U, Haick H. Arrays of chemisensitive monolayer-capped metallic nanoparticles for diagnostic breath testing. Rev Chem Eng. 2010;26:171-179.
7. Amann A, Corradi M, Mazzone P, Mutti A. Lung Cancer Biomarkers in Exhaled Breath. Expert Rev Mol Diagn. 2011;11:207-217.
8. Amann A, Ligor M, Ligor T, et al. Analysis of exhaled breath for screening of lung cancer patients. MEMO. 2010;3:106-112.
9. Hakim M, Billen S, Tisch U. Diagnosis of head-and-neck cancer from exhaled breath. Br J Cancer. 2011;104:1649-1655.
10. Peng G, Hakim M, Broza YY. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103:542-551.
11. Peng G, Tisch U, Adams O. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nano-technol. 2009;4:669-673.
12. Phillips M, Cataneo RN, Cummin AR. Detection of lung cancer with volatile markers in the breath. Chest. 2003;123:2115-2123.
13. Phillips M, Gleeson K, Hughes JM. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999;353:1930-1933.
14. Poli D, Goldoni M, Corradi M. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878: 2643-2651.
15. van de Kant KDG, Jöbsis Q, van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res. 2012;13:1-23.
16. Peled N, Hakim M, Bunn PA Jr. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012;7:1528-1533.
17. Song G, Qin T, Liu H. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer. 2010;67:227-231.
18. Montuschi P, Santonico M, Mondino C, et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest. 2010;137:790-796.
19. Dragonieri S, Schot R, Mertens BJ, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol. 2007;120:856-862.
20. Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009;180:1076-1082.
21. Fens N, Roldaan AC, van der Schee MP. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy. 2011;41:1371-1378.
22. Ligor M, Ligor T, Bajtarevic A, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med. 2009;47:550-560.
23. Peng G, Trock E, Haick H. Detecting simulated patterns of lung cancer biomarkers by random network of single-walled carbon nanotubes coated with nonpolymeric organic materials. Nano Lett. 2008;8:3631-3635.
24. Dragonieri S, Schot R, van der Schee MP, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer. 2009;64:166-170.
25. Machado RF, Deffenderfer O, Burch T, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005;171:1286-1291.
26. Di Natale C, Macagnano A, Martinelli E. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron. 2003;18:1209-1218.
27. Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine. 2012;8:580-589.
28. Broza YY, Kremer R, Tisch U, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. Nanomedicine. 2013;9:15-21.
29. Hakim M, Broza YY, Barash O, et al. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev. 2012;112:5949-5966.
30. Miekisch W, Schubert JK, Noeldge-Schomburg GF. Diagnostic potential of breath analysis-focus on volatile organic compounds. Clin Chim Acta. 2004;347:25-39.
31. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. Biomed Chroma-togr. 2007;21:553-556.
32. Amann A, Miekisch AW, Pleil JD, Risby T, Schubert J. Methodological issues of sample collection and analysis of exhaled breath. In: Horvath EI, de Jongste JC, eds. Exhaled Biomarkers. Leeds, United Kingdom: Maney Publishing Ltd; 2010:96-114. European Respiratory Monograph, 49.
33. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
34. Brereton RG. Chemometrics: Applications of Mathematics and Statistics to Laboratory Systems. Chichester, United Kingdom: Ellis Horwood; 1990.
35. Miller AB, Hoogstraten B, Staguet M, Winkler. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
36. Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology. 2014;271:6-27.
37. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
38. Nisman B, Nechushtan H, Biran H, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014;9:1568-1572.
39. Krilaviciute A, Heiss JA, Leja M, Kupcinskas J, Haick H, Brenner H. Detection of cancer through exhaled breath: a systematic review. Oncotarget. 2015;6:38643-38657.
40. Capuano R, Santonic M, Pennazza G, et al. The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs. Sci Rep. 2015;5:16491.
41. Fernandes MP, Venkatesh S, Sudarshan BG. Early detection of lung cancer using nano-nose - A review. Open Biomed Eng J. 2015;9:228-233.
42. Nakhleh MK, Broza YY, Haick H. Monolayer-capped gold nanoparticles for disease detection from breath. Nano-medicine. 2014;9:1991-2002.
43. Broza YY, Haick H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. Nanomedicine. 2013;8:785-806.
44. Schistosomes, Liver Flukes and Helicobacter Pylori. Lyon, France: IARC Press; 1994:233-246. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 61.
45. Halliwell B, Gutteridge JM, Cross CE. Free radicals, an-tioxidants, and human disease: where are we now? J Lab Clin Med. 1992;119:598-620.